Abstract: The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.
Abstract: A pharmaceutical formulation includes a Limus family immunosuppressive macrolide on a pharmaceutically acceptable excipient, which may be compounded as suitable for oral administration.
Type:
Application
Filed:
March 31, 2010
Publication date:
February 2, 2012
Applicant:
ETHYPHARM
Inventors:
Frantz Deschamps, Catherine Herry, Jennifer Jung, Fabrice Leboeuf
Abstract: The invention concerns nanocapsules, in particular with an average size less than 50 nm, consisting of an essentially lipid core liquid or semiliquid at room temperature, coated with an essentially lipid film solid at room temperature having a thickness of 2-10 nm. The invention also concerns a method for preparing same which consists in producing a reverse phase of an aqueous emulsion brought about by several temperature raising and lowering cycles. Said lipid nanocapsules are particularly designed for producing a medicine.
Type:
Grant
Filed:
March 2, 2001
Date of Patent:
November 15, 2011
Assignees:
Universite d'Angers, Ethypharm S.A.
Inventors:
Béatrice Heurtault, Patrick Saulnier, Jean-Pierre Benoit, Jacques-Emile Proust, Brigitte Pech, Joël Richard
Abstract: The invention relates to low-dose tablets obtained by directly compressing microgranules essentially constituted of a neutral support covered by a polymeric layer containing at least one pharmaceutically acceptable polymer and permitting the modified release of active substances in an aqueous medium, to which an active layer containing at least one active substance is applied. The inventive tablets advantageously exhibit a matrix effect similar to that obtained with conventional matrix tablets that depends on the nature of the polymer(s) used for the constitution of the polymeric layer. This matrix effect makes it possible to modify the release profile of the transported active substance based on the type of the polymer used. These tablets are particularly suited for realizing low-dose tablets. The invention also relates to a method for producing these tablets and to the use thereof, particularly for administering active substances in low to very low doses.
Type:
Grant
Filed:
November 10, 2004
Date of Patent:
October 4, 2011
Assignee:
Ethypharm
Inventors:
Pierre Tchoreloff, Bernard Leclerc, Guillaume Benoist, Laurent Bertocchi
Abstract: Granules and coated granules, characterized in that they contain the following: a core containing at least one active ingredient which is optionally associated with at least one waxlike compound and optionally at least one polymer and/or binding agent; at least three successive layers of coating from the core outwards; a functional polymer coating (1) optionally containing a waxlike compound, enabling immediate, delayed or prolonged release, which can have a structure which is different from that of the first but which has a complimentary release function and which conditions the suspension medium.
Abstract: The present invention relates to an injectable pharmaceutical composition with gelling properties containing:—an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein said organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein: R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups, Its use as a vector for the release of active principles, as well as its process of preparation.
Abstract: Oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcohol solution, or a neutral carrier rendered insoluble in water or an alcohol solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the whole comprises at least one coating based on at least one hydrophobic polymer.
Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.
Type:
Application
Filed:
June 25, 2010
Publication date:
June 30, 2011
Applicant:
ETHYPHARM
Inventors:
Bruno CRIERE, Pascal SUPLIE, Philippe CHENEVIER
Abstract: Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.
Abstract: Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions.
Type:
Grant
Filed:
October 3, 2003
Date of Patent:
January 4, 2011
Assignee:
Ethypharm
Inventors:
Bruno Criere, Pascal Suplie, Philippe Chenevier, Pascal Oury, Keith S. Rotenberg, George Bobotas
Abstract: Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.
Abstract: The invention concerns a microgranule consisting of a core coated with at least a coating layer, said coated core comprising at least an active principle. The invention is characterised in that the core and said coating layer contain each between 80 and 95 wt. % of active principle, the complement to 100% consisting of at least a binding agent, and the coated core has a substantially spherical shape. The invention also concerns the method for making such microgranules.
Abstract: The invention relates to a directly-compressible gastro-resistant spheroid. The spheroid comprises: (i) a core containing one or more active substances; (ii) a flexible, deformable film which directly coats the aforementioned core and which comprises an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides, the fatty acids of which include at least 8 carbon atoms; and (iii) an outer water-dispersible layer containing at least one disintegrating agent. The invention further relates to multiparticular tablets comprising said spheroids.
Abstract: The invention concerns coated particles with prolonged release, a method for preparing same and multiparticulate tablets comprising said coated particles.
Abstract: Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions.
Type:
Application
Filed:
January 13, 2010
Publication date:
May 6, 2010
Applicant:
ETHYPHARM
Inventors:
Bruno Criere, Pascal Suplie, Philippe Chenevier, Pascal Oury, Keith S. Rotenberg, George Bobotas
Abstract: The invention concerns an improved multiparticulate tablet disintegrating in the mouth in contact with saliva in less than 40 seconds. The invention is characterized in that it is based on particles of coated active principle, said particles having intrinsic compression properties and a mixture of carriers, the proportion of carrier mixture relative to coated active principle particles being 0.4 to 6 parts by weight, the carrier mixture comprising: a disintegrating agent; a diluting soluble agent with binding properties; a lubricant; a permeabilizing agent; and advantageously lubricants, sweeteners, flavoring and coloring agents, the proportion of disintegrating agent and soluble agent relative to the tablet mass being 1 to 15 wt. % for the former and 30 to 90 wt. % for the latter.
Type:
Grant
Filed:
March 6, 2006
Date of Patent:
April 13, 2010
Assignee:
Ethypharm
Inventors:
Charles Chauveau, Jean-Marc Zuccarelli, Nourredine Nouri, Maryvonne Barbero
Abstract: The invention relates to a heat-sensitive composition in liquid form, containing: an organic hydrophobic liquid; an organogelling substance, the molecules of which can be bound to one another by low energy linkages; and a bioactive substance, which switches to organogel form upon coming into contact with a physiological fluid during the administration thereof into an animal body, in particular, a human.
Abstract: This invention pertains to an orally disintegrating multilayer tablet wherein it comprises at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and optionally a pore-forming agent.